Sponsor Overview
Explore verified public information about Diakonos Oncology Corporation's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 0 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
No evidence found.
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Diakonos Oncology Inc. is a biotechnology company dedicated to the development of immunotherapies to treat late-stage cancers through a novel approach to Dendritic Cell Vaccines. DOC1021 is a multi-step process that harnesses the patient’s natural immune response, utilizing the manner in which the body mounts an anti-viral response to target and eliminate cancer cells. Currently, access to our Dendritic Cell Vaccine can be obtained through enrollment in one of our clinical studies for Glioblastoma Multiforme (NCT04552886) and Pancreatic Adenocarcinoma (NCT04157127). The objective of these clinical studies is to evaluate patient safety and efficacy For expanded access use to our investigational products, we encourage patients to contact us at expandedaccess@diakonosoncology.com for an evaluation. Diakonos Oncology will assess each request on a case-by-case scenario; however, we cannot guarantee that investigational products will be made available. In any requests for expanded access use, please consider the following the US Food and Drug Administration guidelines for Expanded Access Programs. Available Therapies via Single-Patient EA Dendritic Cell Vaccine for the treatment of individuals diagnosed with Glioblastoma Multiforme and Pancreatic Adenocarcinoma.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.